Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate
- 19 January 2015
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 107, 403-408
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Targeting the PI3K/mTOR Pathway in Pediatric Hematologic MalignanciesFrontiers in Oncology, 2014
- Childhood and adolescent cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive NeuroblastomaCancer Research, 2013
- Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical IntegrationFrontiers in Oncology, 2013
- Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatmentBMC Medicine, 2012
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome ResistanceOncotarget, 2012
- Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated NanoparticlesPLOS ONE, 2012
- Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivoInternational Journal of Cancer, 2011
- Targeting PI3K in neuroblastomaJournal of Cancer Research and Clinical Oncology, 2010
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of RapamycinACS Medicinal Chemistry Letters, 2010